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Summary.-In patients with disseminated malignant melanoma an optimal method
of immunization with irradiated tumour cells was developed by reference to an
in vitro assay for circulating specific serum inhibitors of cell mediated cytotoxicity.
This immunization protocol consisted of the intradermal inoculation of 2 x 107
irradiated allogeneic melanoma cells admixed with 50 ,ug of percutaneous BCG.
This method of immunization induced a significant but transient fall in the specific
inhibitory effects of the sera on tumour directed cytotoxic activity of the patients'
lymphocytes.
In a pilot group of 30 patients with disseminated malignant melanoma being
treated with chemotherapy (DTIC and vincristine) the immunotherapy was given
midway between courses of the cytotoxic drugs. There was a correlation between
the effects on circulating inhibitor and clinical outcome. The number of objective
regressions occurring in this small pilot group was surprisingly high (17/30) and
these clinical effects, although obtained in a series without concurrent controls, are
presented for discussion.
We suggest that the approach illustrated by this study, employing in vitro assays
of tumour directed immune responses, may provide a suitable rational basis for the
use of active immunotherapy as an adjunct to chemotherapy in the treatment of
malignant disease.
FOR THE RATIONAL application of
immunotherapy in human cancer many
practical questions have to be answered.
What is the best form of treatment?
What dose is needed? By what route
should it be given? How often? The
answers to such questions can be most
readily ascertained by examination of
the effects of the treatment detected by
assays of tumour specific immunological
reactions. Previous studies (Currie,
1973a, b) have suggested that such in-
formation may be gleaned by assaying the
specific inhibitory effects of the patients'
sera on tumour directed cytotoxic lympho-
cytes. Such studies have incriminated
soluble tumour specific antigen in such
serum inhibitory effects and, further-
more, they showed that immunization of
patients with disseminated malignant
melanoma, by inoculation of irradiated
melanoma cells, led to a rapid but
transient fall in the levels of such antigen
in the serum. The use of this assay has
allowed the development of immuniza-
tion procedures in malignant melanoma
patients which seem to be optimal for
producing such changes, i.e. changing the
serum activity from a state of antigen
excess to one of antibody excess.
In the course of these earlier studies,
which were purely investigative and in
no way designed to detect therapeutic
effects, occasional unexpected clinical
responses occurred. Consequently we
were led to perform a pilot study to
determine whether active immunotherapy
using irradiated tumour cells could beG. A. CURRIE AND T. J. MCELWAIN
TABLE
Site of Length of Previous
primary history treatment
Abdominal 6 years Sugery and
wall irradiation
341 y 48 L arm 3 years
345 , 71 L eye 2 years
353 y 58 R arm 2 years
352 y 51 L leg 4 years
355 d 49 R leg 2 years
359 y 44 R leg 2 years
356 y 39 L leg 5 years
357 c 40 Unknown 1 year
Irradiation of
axilla
Enucleation of eye
Irradiation of
axilla
Intra-arterial
melphelan and
surgery
Block dissection
Pre-treatment Response to
status treatment
Massive intra-abdominal Dramatic regression of
tumour involving gut mass but died after 3
months with intestinal
obstruction
Extensive involvement
of axilla, arm and
breast
Massive hepatomegaly
Disease in R axilla,
breast, arm, lungs and
liver
Subcutaneous deposits
leg, neck, breast and
shoulder
Massive cutaneous
involvement R leg
Surgery only Multiple s.c. nodules
R leg
Surgery only Pelvis, lung, liver and
R groin
Spinal irradiation
360 Y 78 Subungual 1-5 years Surgery only
L great
toe
361 Y 42 Anus 2 years Surgery and
irradiation to head
Subcutaneous, bone,
lungs, and liver
involvement
Multiple subcutaneous
nodules L leg
Cerebral, lung, liver
and subcutaneous
metastases
365 d' 24 Chest 1 year Axillary node Very extensive subcu-
clearance taneous and lymphnode
nodules, cerebral and
orbital metastases
358 9 17 L ankle 3 years Endolymphatic Multiple subcutaneous,
32p and block liver, lungs and pelvic
dissection metastases
32 Back
31 Unknown
R eye
Medias-
tinum
Unknown
6 months BCNU, vincristine
and TMCA
1 year Multiple bowel
resections
2 years Enucleation
8 months Irradiation
1 year Biopsy only
381 c3 R pinna 4 years Surgery and
irradiation
Multiple subcutaneous
and liver metastases
Multiple metastases
throughout small bowel
with exteinsive bleeding
leading to severe
anaemia
Massive liver
involvement
Lung, liver, bone and
subcutaneous deposits
Very many subcu-
taneous nodules on
trunk, arms and legs
Multiple subcutaneous
nodules in neck
No response. Died after
4 months
Liver size diminished
after 2 months treat-
ment. Recurred after 8
months and he died 10
months after starting
treatment
No response. Died after
6 months
Complete regression for
8 months, then local
recurrence which res-
ponded when DTIC and
vincristine restarted
Temporary regression
over 50% lasting 2
months
Complete regression (11
months so far)
Regression of all disease
except a solitary lung
metastasis (10 months
so far)
3 months regression of
subcutaneous lesions
(partial) but eventual
death after 10 months
Partial (>50 °0) regres-
gression maintained for
9 months
Temporary partial re-
gression of 2 subcu-
taneous nodules only.
Died after 8 months
No response. Died after
3 months
No response to protocol
but subsequent irradia-
tion of pelvic lesion led
to some local regression
No response. Died after
5 months
No response. Died after
3 months
No response. Died after
3 months
No response. Died after
3 months
Regression of at least
75% ofskin nodules, re-
mains well after 6
months
Partial regression (75%)
of all nodules
Ca,e
no. Sex Age
33S 3 43
362
373
371
372
377
6'
53
56
52
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TABLE-(continued)
Site of
primary
R heel
Nasal
septum
37 L. pinna
59 Back
51 L leg
39 R leg
Length of
history
3 years
4 years
Previous
treatment
Lymphadenectomy
R groin
Surgery and
irradiation
3 years Surgery only
9 years Surgery and
endolymphatic
1251
14 years Recurrent nodules
excised
2 years Surgery and
endolymphatic
32p and BCG
385 S 57 R arm 17 years Recurrent nodules
excised. Irradia-
tion. R axilla
339 c 19 L loin 1 year Block dissection
L axilla
347 9 58 R calf 9 months Surgery only
391 ? 55 R ankle 1 year Endolymphatic
32P and surgery
394 y 56 L calf 6 years Intra-arterial
chemotherapy and
local vaccinia
Pre-treatment
status
Massive subcutaneous
involvement in R leg
Recurrent primary
tumour with involved
neck glands
Subcutaneous and
hepatic metastases
Lung and liver
metastases
Lung metastases
Massive, widespread
involvement R leg
Response to
treatment
No response. Static (for
4 months)
Massive regression of
neck nodes. Primary
did not respond. With-
drew from study after
4 months treatment
Disease has remained
static for 6 months
Regression oflung meta-
stases occurred after 3
courses of treatment
Lung deposits regressed
after 3 courses
Regression of subcu-
taneous nodules occur-
red after 2 courses of
immunotherapy and
chemotherapy
MIultiple subcutaneous No response
and intracutaneous
nodules in R breast
Recurrent subcutaneous Regression occurred af-
nodule on abdominal ter first cycle of treat-
wall ment
Multiple subcutaneous Complete regression oc-
nodules R leg with curred over a period
" suspicious " liver of 6 months. N.B. She
scan was given no chemo-
therapy
Multiple lesions in R No response
groin and a single lung
metastasis
Liver, lung, bone and
subcutaneous
metastases
No response, went
rapidly downhill after
2 courses and died
3 months after pre-
sentation
combined with chemotherapy in patients
with disseminated malignant melanoma.
Disseminated malignant melanoma
presents an awesome clinical problem.
The best single agent for systemic chemo-
therapy currently available is 5(3,3-di-
methyl-triazeno)imidazole-4-carboxamide
(DTIC). The results obtained with this
drug are however, disappointing. In
most of the series so far described, the
incidence of objective regression seems
to be about 20% and these regressions
are frequently very short-lived and often
of little or no clinical value (Luce, 1972).
This communication describes a pilot
study in which specific active immuno-
therapy with irradiated tumour cells was
combined with a chemotherapy regimen
incluiding DTIC. The immunotherapy
was designed by reference to the in
vitro test system and where possible the
effects of the treatment on circulating
antigen levels were monitored. In the
course of this study the incidence of
objective tumour regression was higher
than we had anticipated. Brief clinical
details of these patients are described
and the necessity for an appropriate
clinical trial comparing chemotherapy
alone with chemotherapy plus immuno-
therapy is emphasized.
MATERIALS AND METHODS
Patients studied.-This study was com-
menced in April 1973. All the patients
subjected to the treatment protocol had
biopsy proven disseminated malignant melan-
oma. Because of extensive metastatic dis-
Sex Age
Y 59
3 64
Case
no.
378
354
364
380
382
383
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ease, all the patients were considered un-
suitable for surgical management and some
of them had previously been treated with
irradiation and/or chemotherapy. Brief clini-
cal details are presented in the Table and
indicate the site of original primary, length
of history and previous management. No
patients were started on the treatment
protocol within 8 days of any surgical
intervention such as diagnostic biopsy.
Before treatment, the patients were in-
vestigated to determine the extent of their
metastatic disease. Routine biochemical and
haematological screening was performed, the
urine was examined for the presence of pre-
melanogen; chest x-rays, skeletal surveys,
liver function tests, liver scans and ultra-
sonograms were performed in all cases.
Where indicated lymphangiography and bone
marrow aspirations were carried out. De-
tailed mapping and measurements of all
clinically detectable disease were performed.
Histological confirmation of the diagnosis
was made in all cases but so far examination
of the original primary tumours and appro-
priate grading and classification studies are
incomplete.
Immunization procedure.-Melanoma cells
obtained as previously described (Currie,
Lejeune and Fairley, 1971), were withdrawn
from a liquid nitrogen bank, rapidly thawed
at 37°C and washed 3 times in medium 199.
They were then counted in a haemacytometer
and diluted to give 2 x 107 cells in 0-9 ml
of medium 199. After irradiation (10 Krad
in a 60Co source) BCG was added.
Percutaneous BCG (Glaxo) was reconsti-
tuted and diluted in streptomycin-free
medium to a concentration of 500 ug/ml;
0.1 ml of this suspension was then added
to the 0 9 ml of tumour cells. This dose
of BCG contained approximately 2 x 106
live organisms. This 1 ml of cells and BCG
were then inoculated intradermally in 8
distinct sites in one limb at a time. Inocula-
tions were made only into limbs that were
macroscopically free of tumour. Each pati-
ent in the final protocol received allogeneic
cells. For repeated immunizations a dif-
ferent batch of donor cells was emploved
each time (i.e. derived from different donor
patients). This was done to maximize any
possible helper effect due to histocompati-
bility antigens on the donor cells and to
minimize any possible interference by the
development of high titre anti-HLA anti-
bodies which might abrogate any such
"help ".
Chemotherapy.-5(3,3-dimethyl-triazeno)-
imidazole-4-carboxamide (N.S.C. 45388) was
administered intravenously at a dose of
2-5 mg/kg body weight for 5 consecutive
days. On the first day the patients also
received a single intravenous injection of
vincristine at a dose of 1@4 mg/M2. Anti-
emetic drugs were also given to minimize
nausea and vomiting.
This chemotherapy regimen is remarkably
non-toxic. In no patients did sufficient
marrow toxicity occur to necessitate changes
in the protocol. Very mild peripheral neuro-
pathy, due no doubt to the vincristine,
occurred in 2 patients but did not constitute
a major problem. In one patient (ME360)
the chemotherapy was stopped after 2
courses because she found the nausea dis-
tressing. In one further case (ME347) no
chemotherapy was given as the patient
lived too far away and refused admission to
hospital at monthly intervals to receive
chemotherapy. The results of this case are
included in the Table because this patient
showed a dramatic regression, due apparently
to immunotherapy alone.
In the week following chemotherapy,
occasional patients complained of lassitude,
but on the whole the protocol was exception-
ally well tolerated.
Combined immunotherapy - chemotherapy
protoeol.-In all these studies the patients
started treatment with the immunization
procedure. There is Ino rationale for this
other than the fact that the patients could
be investigated without the influence of
prior chemotherapy affecting their immuno-
logical reactivity.
The major variable in a combined regi-
men such as this is the time interval between
treatments. Currie and Bagshawe (1970)
have shown in an animal model that the
interval between chemotherapy and any
subsequent immunotherapy is of crucial
importance. In that particular study an
interval of 12-14 days was found to be
optimal. In different test systems, however,
the intervals needed for an optimal effect
may vary. This may well depend on both
the tumour studied and the chemotherapeutic
agent employed.
The final protocol chosen for the pilot
study, based on the animal data of Cu-rie
and Bagshawe (1970) and the known
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immunosuppressive properties of the chemo-
trherapy, is illustrated in Fig. 1. Starting
with immunotherapy there was a delay of
14 days, followed by 5 days chemotherapy.
T'he next cycle commenced wN-ith immuno-
therapy given 14 days from the end of the
previous course ofchemotherapy. The treat-
nment continued, wvhere possible, for 6 cycles
and the chemotherapy w-as then omitted
and the immunotherapy continued at, 28-day
intervals.
Assays of circalcating soluble m.elanomia-
specific antigen. Where technically feasible,
patients were studied by the in vitro assay
previously described which employed short-
term cultures of target cells (Currie and
Basham, 1972; Currie, 1973b).
Sera were obtained at frequent intervals
before and after treatment and stored at
-20°C before testing. They were tested
for specific inhibitory activity by incorpora-
tion at 5%o into the lymphocyte suspensions
before seeding onto melanoma target cells.
The results were expressed as an inhibitory
index w%hich was derived from the crude cell
counts thus:
Inhibitory index
No. of cells killed in 50o AB serum
-No. of cells killed in 5% patient's serum
No. of cells killed in 50o AB serum
x 100
where
No. of cells killed
mean cell number in serum only w%vells.
-mean cell number in lymphocyte
+ serum wells
Specificity ofthe inhibitory effect was checked
routinely by incorporating the test sera into
lymphocyte-target cell combinations from
patient,s writh renal parenchymal cell car-
cinoma and results are quoted only from
assays in -which no nonspecific effects were
detectable.
RESULTS
Effects of immrunization with irradiated
alloqeneic melanoma cells
Previous studies (Currie, 1973b) have
shown that active immunization with
irradiated autologous tumour cells leads
to a fall in the serum levels of circulating
soluble antigen, present either free or
bound to antibody. In that the cyto-
toxicity of peripheral blood lymphocytes
from malignant melanoma patients show-
ed a pattern of histogenic cross-reaction
(Currie and Basham, 1972), it was decided
to assess the effects of immunization of
these patients with irradiated allogeneic
melanoma cells. Figure 2 shows the
results obtained in 5 patients with dis-
seminated melanoma. In each case there
was a dramatic, rapid but transient fall
in circulating serum inhibitory activity
at least as good as that previously
obtained with autologous cells (Currie,
1973b). As the use of allogeneic cells
made the immunizatioin procedure prac-
ticable in all the patients, it was adapted
as the standard immunization method in
the current protocol.
Effect of admixing BCG with the tunmour
cells
It was previously alleged that large
ntumbers of inioculated tuimour cells were
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t DAYS
Via. 2. -ffect of immunlilzation (intradermally) with irrcadiated allogeneic melainoma cells on serum
levels of specific inhibitory activity in 5 patimts with (lisseminated1 malignant melanoma. The
arrowN dlen-ote. the time of injectionl.
needed to evoke a detectable in vitro
effect (Ikonopisov et al., 1970; Currie et
al., 1971). It was found that the incor-
poration of BCG into the cell suspension
and the use of the intradermal route
allowed the use of low numbers of cells
for immunization, 2 x 107 allogeneic cells
plus 50 lig BCG, giving a predictable fall
in serum inhibitory activity (circulating
antigen). This is in accord with the
findings of Sokal, Aungst and Han (1972)
who found that delayed hypersensitivity
reactions to human tumour cell lines
could be readily evoked using a similar
immunization procedure.
What is the effect of BCC alone?
In the case illustrated (Fig. 3) one of
3 patients so tested was first given intra-
dermal BCG only, followed later by a
mixture of BCG and allogeneic melanoma
cells. It can be seen that the BCG
alone had no detectable effect on the
serum inhibitory activity level, whereas
the inclusion of tumour cells in the
mixture led to a prompt fall. This was
the result in all cases tested in this way.
It seems probable that the BCG given
in this manner is acting as a local adju-
vant rather than a nonspecific systemic
" booster " of immunological reactivity,
although further studies will be needed
to elucidate the precise role of the
BCG.
Efffect of the imnmnnotherapy--chemnotherapy
protocol on 3erum. antigen level8
The first case treated with this com-
bined protocol (ME338) had serial mea-
surements of specific serum inhibitory
activity made. Details of this ca3e are
presented later in this paper. However,
the impetus for carrying out this pilot
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FiG. 3.-Serum inhibitor levels in a patient (ME347) treated first with intradermal BCG only and
then with BCG plus allogeneic melanoma cells. BCG alone had no effect on the serum inhibitory
activity whereas the addition of tumour cells led to a significant fall.
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FIG. 4.-Serial estimations of circulating " melanoma specific antigen " in ME338 during the first
3 treatment courses. The stepwise decline in serum activity was associated with regression of his
massive retroperitoneal tumour.
study was provided by the fact that his
massive intra-abdominal tumour under-
went a dramatic regression while the in
vitro studies were being performed. The
serial levels of serum inhibitor in this
case are illustrated in Fig. 4. Following
the first immunization there was a rapid
decline in serum inhibitor levels. This
recovered quite rapidly and was appa-
rently unaffected by the chemotherapy;
12
however, after the next immunization
there was an even greater and more
sustained fall in inhibitor levels in the
serum. After the third cycle of treat-
ment the level had fallen to zero. This
sequence of events occurred concurrently
with the disappearance of his massive
tumour, although in this first case the
timing schedule was not strictly adhered
to. The levels of inhibitor remained at
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FIG. 5.-Serum inhibitor levels in 2 patients (ME352 and ME360) with skin metastases duringM
the first 2 courses of treatment. The prompt fall in inhibitory activity occurred concurrently
with tumour regression in both cases.
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FIG. 6.-Two cases (ME347 and ME362) with massive hepatic involvement. ME347 underwent
a temporary regression whereas the disease in ME362 progressed inexorably. The serial measure-
ments of inhibitory soluble antigen correlated with the clinical picture in each case.
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zero until his eventual death from in-
testinal obstruction.
In Fig. 5 and 6, 4 more cases are
illustrated throughout the first 2 cycles
of treatment. Figure 5 shows the results
obtained in 2 women with disease con-
fined to the subcutaneous tissues, although
in one (ME352) it was widely dissemin-
ated. In both cases the first cycle of
treatment led to a profound and sustained
fall in inhibitor levels. Objective regres-
sion (complete in ME352 and partial in
ME360) occurred at the same time. In
Case no. ME360, the partial regression
(at least 5000 of all measurable disease)
was maintained for 11 months, whereas
the total regression in ME352 was main-
tained 9 months before recurrence of a
single subcutaneous nodule. Moreover,
the patient with maintained partial re-
mission (ME360) lhad received only 2
courses of chemotherapy. In both cases
inhibitory activity remained undetectable
over the first 6 months.
In Fig. 6, 2 patients are illustrated
who presented with much more advanced
disease. Both previously had primary
retinal tumours treated surgically and
had both presented with subsequent
massive liver involvement. Case no.
ME345 survived for 13 months after
starting treatment and during that time
objective regression, as indicated by
shrinking of both liver size and of a
large palpable epigastric nodule, occurred
and lasted approximately 2-3 months.
In Case no. ME362 the liver was, at
presentation, massively involved and was
quite unaffected by the treatment. Sub-
sequent intrahepatic infusion of DTIC
gave subjective relief of liver pain but
no evidence of objective regression was
obtained and she subsequently died 14
weeks after presentation.
There is, as can be seen from Fig. 6,
a striking correlation between the in
vitro assay results and the clinical out-
come. InME362 thelevelsofcirculating in-
hibitor were high and rose progressively,
beingvirtuallyunaffectedbythetreatment,
whereas ME345 showed a fall in inhibitory
activity after the first 2 immunizations.
The results obtained from the in
vitro assays seem to indicate that serial
assays of circulating tumour specific
inhibitor correlate with the clinical out-
come of the combined immunotherapy-
chemotherapy regimen. Furthermore,
they support the notion that the im-
munization procedure is capable of affect-
ing the patient's own tumour directed
immunological reactions in a meaningful
manner.
Clinical results
The definition of objective regression
in malignant melanoma is difficult. By
convention such a regression is often
defined as a 5000 reduction in the
diameter of measurable lesions lasting
at least 30 days and in the absence of
disease progression elsewhere. Lack of
progression of the disease, alone, although
possibly an important therapeutic effect
is much more difficult to assess. In order
to avoid some of the semantic problems
associated with such definitions, brief
details of the cases treated in this study
are shown in the Table, and some of
those undergoing objective regression are
described in some detail.
ME338. In 1967 this man, then aged
36, noticed an area of pigmented skin on
his anterior abdominal wall which was
spreading rapidly and eventually started
to bleed. This lesion was widely excised
and w,as histologically diagnosed as malignant
melanoma. At the same time an involved
lymph node was removed from his left
axilla. After an interval of 6 months
another involved lymph node became pal-
pable in the right axilla and this was also
excised. One month later a local recur-
rence was excised from the original primary
site. In the following 2 years he developed
several subcutaneous metastases on the
chest wAall, abdomen and right arm and
these were treated with irradiation with
some success. Later in 1972, however, his
general health deteriorated and he was
found to have severe anaemia. This was
found to be due to bleeding from the gut
and he was managed by periodic blood
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transfusions. He was referred to this centre
complaining of abdominal discomfort and
distention. On examination and after de-
tailed investigation, he was found to have
a large intra-abdominal mass involving the
left para-aortic lymph nodes (by lymphangio-
graphy) and a grossly abnormal liver scan.
At laparotomy he was found to have a
massive retroperitoneal tumour. A super-
ficial lobe of this tumour was invading both
duodenum and jejunum and this part of the
tumour and involved gut were excised,
leaving behind the larger deeper lobe of the
tumour. Histologically the mass excised
was found to consist of poorly differentiated
amelanotic melanoma. He made an excel-
lent recovery from this surgical intervention
and subsequently on palpation of the abdo-
men a fixed mass of approximately 15 cm
in diameter could be felt lying to the left of
the midline at the level of the umbilicus.
In May 1973 he was immunized with
irradiated tumour cells and BCG and started
on the combination treatment. During each
course of chemotherapy it was noticed in
this case that the immunization sites flared
up with induration, erythema and tender-
ness, subsiding again after the cessation
of chemotherapy. Over the first 3 months
of treatment the palpable abdominal lesion
became much smaller in diameter, shrinking
to approximately 5 cm in diameter. How-
ever, despite this excellent progress he
eventually (42 months after starting treat-
inent) had several grand mal epileptic
seizures. Despite negative investigations for
cerebral deposits, he was treated with
cranial irradiation. Approximately 1 month
later he suddenly became extremely ill,
developing abdominal obstruction and died.
At autopsy the only detectable tumour was
the retroperitoneal lesion to which many
loops of bowel adhered; his liver, para-aortic
lymph nodes and brain were free of disease
and the tumour mass consisted of necrotic
debris with a small rim of viable tumour.
ME365.-In 1968 this lady, aged 39,
noticed that a mole on her left thigh was
enlarging and, being a nurse, she asked for
it to be removed. Histologically this lesion
was reported to be benign. However, 4
years later she developed a pea-size nodule
under the excision scar and this was widely
excised and found to be a malignant melan-
oma. Six months later she developed a
mass in her left groin and on investigation
there was evidence of widespread disease.
Apart from the mass of nodes in the left
groin, lymphangiography demonstrated mas-
sive intrapelvic node involvement on the
left side. There were several large lung
metastases visible on chest x-ray, and a
liver scan showed several cold areas in the
right lobe of the liver.
She was therefore started on immuno-
therapy and chemotherapy. Within 3
months the mass in the left groin had re-
gressed completely and the pelvic mass was
much smaller. After a further 3 months,
at which time the chemotherapy was stopped,
the liver scan was reported as normal, the
cold areas having resolved, and the only
detectable abnormality at that time was a
single small nodule in the lower lobe of her
right lung and a small pelvic node on the
left side. She continued on monthly im-
munotherapy and was given a low dose of
local irradiation to the lesion in the right
lung. Bothi these small residual lesions, in
lung and pelvis, have remained static now
for 5 months. At 11 months after starting
treatment she remains fit and Nell with no
evidence of disease elsewhere.
ME352.-This lady, aged 51, presented
in 1970 with a primary malignant melanoma
on her left calf. This was widely excised
and the site skin grafted. She remained
well for 2 years until a local subcutaneous
recurrence occurred in her left lower leg.
At the same time she developed acute
appendicitis. At appendicectomy no evi-
dence of intra-abdominal metastasis was
found. The local lesion on her leg was
excised. However, 6 months later multiple
subcutaneous nodules developed on her left
leg and these were treated with intra-arterial
melphelan. This had no effect and so most
of the lesions were surgically excised. Ano-
ther 6 months later she presented with
further deposits on the leg but now there
were palpable metastases in the scalp, on
the left shoulder and in the left breast. The
lesion in her breast and most of those on
the leg were excised. Histologically they
were all shown to be deposits of malignant
melanoma. The subcutaneous lesions on
the scalp, on the shoulder and those remain-
ing on the leg were left alone. There was
no evidence of visceral involvement from
clinical examination or from the investiga-
tions performed. She was therefore started
on the combiniation treatment protocol.
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After 3 imontlhs treatmnent, all the nodules
regressed completely and she remained wNell
for a further 7 months. However, 10
months after starting the treatment local
recurrence occurred in the left leg and this
was surgically excised. In the 2 wN-eeks
following surgery there was a rapid, almost
explosive, growth of multiple subcutaneous
lesions on the left leg with involvement of
lymph nodes in the left groin. She had by
this time been off chemnotherapy for 4
months but had continued with monthly
immunizations; she was therefore started on
DTIC and vincristine again and this pro-
duced a transient regression of her recurrent
disease which wAas maintained for a further
2 months.
ME382. This patient, a lady aged 44,
originally presented in 1960 with a pigmented
lesion on her left calf; it had been there for
many years but in the previous few wNeeks
had grown larger and had occasionally
bled. This wNas excised surgically and on
histological examination was described as
a " junctional naevus with a central nodule
showing verv early malignant change".
She remained well for a further 12 years
after this episode, until discovering a sub-
cutaneous nodule in the left thigh. This
was excised and on histological examination
shown to be overt malignant melanoma.
Six months later the inguinal lymph nodes
on the left side became enlarged and she
underwent block dissection of the left
groin. Two of the excised nodes wNere found
to be involved, the uninvolved nodes showing
marked reactive hyperplasia. Six months
later yet another nodule developed in her
left thigh. This was excised and histo-
logically wvas " malignant melanoma con-
sisting of plump spindle cells with abundant
mitotic figures ". After yet another 6
months, 2 small nodules of malignant
melanoma ere excised from her scalp and
this time a chest x-ray revealed the presence
of multiple lung metastases.
On examination, she was a healthy
looking woman with no evidence of sub-
cutaneous disease or other clinically detect-
able manifestations of metastatic melanoma.
On investigation, the only detectable disease
wAas confined to the chest.
She was therefore started on the current
immunotherapy-chemotherapy protocol with
minor modifications of the chemotherapy.
No vincristine wNas given and the dose of
DTIC employed -was 250 mg/in2. She toler-
ated the treatment w-ell, not evein requiring
hospitalization for the chemotherapy. After
3 months treatment, the chest x-ray showed
evidence of regression of the inetastatic
lesions. No further disease has recurred in
other sites and she remains extremely fit
after a further 6 months.
Of the 30 cases treated in this pilot
study, objective regression of disease
(partial or complete) occurred in a total
of 17 (i.e. 570/o). In that the regression
rate to be anticipated from the use of
chemotherapy alone is in the order of
20%, we believe that the active immuno-
therapy may have a significant adjuvant
effect. We are therefore encouraged to
embark on the appropriate controlled
trial of immunotherapy plus chemo-
therapy v1s chemotherapy alone.
DISCUSSION
The systemic deployment of immuno-
logical responses for the treatment of
cancer patients is once again under
investigation in many c3ntres. However,
most controlled studies of immunotherapy
have so far provided remarkably little
evidence of clinical benefit. For instance,
active immunotherapy using autologous
irradiated tumour cells has been shown
to be without effect in patients with
glioblastoma multiforme when used as
an adjunct to radiotherapy in a random-
ized controlled trial (Bloom et al., 1973).
Furthermore, nonspecific active treat-
ment with BCG, despite intense investiga-
tion, has been shown to be ineffective in
maintaining remission in acute lympho-
blastic leukaemia (Heyn et al., 1973;
MRC, 1971) and in Burkitt's lymphoma
(Ziegler and Magrath, 1973). However,
Sokal (1973) has claimed, using historical
controls, that immunotherapy can be
beneficial in chronic myeloid leukaemia.
Furthermore, also employing historical
controls, Gutterman and his co-workers
(1973) have alleged that immunotherapy
using BCG is of value in the treatment
of malignant melanoma. The use of
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both irradiated blast cells and BCG has
been shown to prolong remission length
and survival in patients with acute
myelogenous leukaemia previously
brought into haematological remission
with chemotherapy (Powles et al., 1973).
These effects, obtained in a controlled
trial, indicate that under some circum-
stances an immunological procedure may
significantly influence the course of a
malignant disease. Although the results
of this study do not constitute a major
advance in the treatment of acute myelo-
genous leukaemia, in that the patients
still die of the disease, it is so far one of
the few controlled trials which clearly
demonstrate an effect due to immuno-
therapy. Vogler and Chan (1974) have
recently described a similar prolongation
in remission in the same disease using
BCG alone as the immunotherapy. Such
studies seem to illustrate the potential
value of appropriate combinations of
immunotherapy with other treatment
methods.
In experimental animals such an
adjuvant activity of immunotherapy has
been described by Haddow and Alexander
(1964). Currie and Bagshawe (1970) have
described the successful combination of
chemotherapy with a form of immuno-
therapy and the value of this sort of
combination has been confirmed in ex-
perimental animals by other workers
(Pearsoil et al., 1972). However, the
combination of an immunization pro-
cedure with a potentially immunosup-
pressive form of chemotherapy will ob-
viously be complex. The current en-
thusiasm for giving chemotherapy inter-
mittently in high doses could perhaps
permit the inclusion of an immunization
procedure between courses. Cheema and
Hersh (1971) have investigated some of
the effects of chemotherapy on lymphoid
cell function. Many agents given in a
single large dose lead to a severe depres-
sion of lymphoid cell function which does,
however, recover, often with rebound,
after 8-10 days. DTIC has little
immunosuppressive activity (Bruckner,
Mokyr and Mitchell, 1974) and the kinetics
of any effect it might have on lymphoid
cells is unclear. As DTIC is currently
the drug of choice in the treatment of
disseminated malignant melanoma, the
optimal immunization technique already
described was incorporated into a cyclical
combination with this drug.
The immunization technique employed
in this study was extremely well tolerated.
Local reactions at the injection sites
were, however, variable. In the majority
of patients the local lesions produced
rarely caused inconvenience or pain, were
usually less than 1 cm in diameter and
were not associated with any overt
systemic disturbances such as fever,
malaise or impaired liver function. After
several cycles of treatment, the reactions
did become more severe in several pa-
tients. After 3 or 4 monthly immuniza-
tions the dose of BCG used was halved
in those patients whose previous injection
site reactions were over 1 cm in diameter.
In such hyper-reactive patients, inocula-
tions of allogeneic melanoma cells alone
frequently evoked vigorous delayed hyper-
sensitivity reactions. In one case (ME
352) inoculation of autologous tumour
cells evoked such a reaction. Unfor-
tunately, autologous cells were not avail-
able in most of the cases treated. Where
possible, immunization was confined to
the upper limbs because inoculation intra-
dermally into the thigh region, especially
in women, occasionally led to ulceration,
due apparently to local fat necrosis.
It was noticed that in those patients
undergoing tumour regression the local
immunization site lesions were often
more aggressive. In some patients there
was little or no reaction around the
injection sites; in none of these did
tumour regression occur. This finding
suggested that the ability of the patients
to mount a delayed hypersensitivity
reaction may be important in determining
the effects of the treatment. An attempt
to examine this possibility gave somewhat
enigmatic results. Eight of the patients
were sensitized to dinitrochlorobenzene
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(DNCB) and then skin tested 14 days
later. Three patients were completely
unreactive to any test concentration of
DNCB whereas the other 5 all gave
normal reactions. The 3 negative DNCB
cases, however, all produced dramatic
local reactions to the BCG-tumour cell
innoculum and all 3 underwent objective
tumour regression (ME352, ME356, ME-
381). One of the DNCB positive cases
gave a very brisk delayed hypersensitivity
reaction even to the lowest test concen-
tration and yet failed to produce local
responses to the BCG and tumour cell
mixture or to show any sign of tumour
regression. In other words, DNCB skin
reactivity did not predict eventual re-
sponse to the immunization schedule.
Whether or not DNCB skin reactivity
constitutes a meaningful assay of delayed
hypersensitivity reactions in general re-
mains unclear at present.
The number of objective regressions
occurring in this small pilot study was
surprisingly high. Previous studies at
this centre using chemotherapy of various
types (including DTIC) have provided a
very low incidence of objective regres-
sions. Using DTIC, our experience has
not matched that of many other centres-
of the last 16 cases so treated regression
occurred in only one.
Luce and his colleagues (Luce et
al., 1970) reported a clinical study in
which DTIC was used in 110 patients
with disseminated malignant melanoma.
Objective anti-tumour effects were seen
in 21 of these (i.e. 19%). In a small
study of 19 cases, Ahmann and his
colleagues (Ahmann, Hahn and Bisel,
1974), combined DTIC with vincristine
in a manner similar to our present chemo-
therapy regimen, and described objective
responses in only 4 (i.e. 21O/ ). Luce
(1972), in reporting the results of the
South AAWest Cancer Chemotherapy study
group, showed that objective regression
was obtained in 26% of women but only
in 130% of men treated with DTIC. He
concluded that DTIC " has proven, in
extensive trials, to be the most effective
single agent yet developed ". Combina-
tion with other agents has so far provided
little or no added advantage over the
use of DTIC alone. Luce (1.972), describ-
ing pooled data from several trials of
DTIC, noted that out of a total series
of 733 cases objective regression was
obtained in 169 (23%).
There are some clues from this study
that the immunotherapy procedure may
well be playing an important role. The
correlation between clinical effects and in
vitro assay results, although not studied
in all the cases, is nevertheless striking.
Furthermore, the regression obtained in
the one patient (ME347) treated with
immunotherapy alone is highly suggestive
and, taken with the strikingly high
incidence of objective regression occurring
in this group, compared with our own
historical controls or with other published
studies of patients treated with chemo-
therapy alone, argues in favour of the
immunotherapy acting as an important
adjunct to chemotherapy.
Objective regression, however defined,
may not necessarily have much clinical
relevance. It does, however, provide a
visible manifestation of anti-tumour acti-
vity and therefore allows an assessment
of a treatment protocol at an early stage.
The effects of active immunotherapy plus
chemotherapy on the overall survival
(as well as regression rate) of patients will
obviously have to be assessed in some
sort of controlled clinical comparison.
The relative effectiveness of immuno-
therapy as an adjunct to chemotherapy
in the treatment of disseminated malig-
nant melanoma can only be ascertained
by the use of such concurrent controlled
trials. Furthermore, evidence obtained
from this study should allow the design
of rational combinations of immuno-
therapy and chemotherapy in situations
of greater clinical relevance such as the
treatment of high risk primary tumours
and in the prophylaxis of recurrence
following surgery.
This study illustrates our approach
to the development and clinical applica-
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tion of a form of so-called immuno-
therapy. We believe that the essential
features of such an approach must include
assays of the effects of the immuno-
logical manipulation employed on some
aspect of tumour specific host reactivity.
At present an in vitro assay for the
detection of circulating soluble tumour
specific inhibitory factors seems to be
the most appropriate test system for
determining the most effective method
of immunization and allowing its subse-
quent incorporation into a combined
regimen with chemotherapy.
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